Beta-Cell Aggregate Suspension for Unstressed Extracellular Vesicle Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing extracellular vesicles (sEV) from beta cells face challenges such as maintaining an unstressed phenotype during culture, scalability issues, and high yield requirements for therapeutic use, particularly in the context of treating Type 1 diabetes.
Innovation Solution
A method involving culturing beta cells as aggregates in suspension under stirring conditions in a serum-free medium, optimizing parameters like stirring speed, duration, and cell density to preserve the unstressed phenotype and enhance vesicle production, using a stirred tank bioreactor for large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If beta cells are cultured in traditional adherent conditions, then cell viability is maintained, but extracellular vesicle production is insufficient for therapeutic use
Solution Approach 1:
The patent transitions beta cells from static adherent culture to dynamic suspension culture with controlled stirring. This dynamic condition enhances extracellular vesicle release while maintaining cell viability through optimized agitation parameters (60-160 rpm), resolving the contradiction between production quantity and productivity.
Solution Approach 2:
The patent modifies key culture parameters including switching to suspension culture, optimizing stirring speed (60-160 rpm), controlling culture duration (4-24 hours), and using serum-free medium. These parameter changes collectively increase extracellular vesicle yield while maintaining productivity for therapeutic applications.
2Quantity of substance
If beta cells are exposed to stress conditions in culture, then extracellular vesicle release increases, but the phenotype becomes pathological
Solution Approach 1:
The patent implements continuous optimized stirring (60-160 rpm) throughout the culture period to maintain steady-state extracellular vesicle release without inducing stress. This continuous gentle agitation preserves the unstressed phenotype while ensuring consistent vesicle production, resolving the contradiction between release quantity and phenotype stability.
Solution Approach 2:
The patent applies partial stress through controlled stirring conditions that are sufficient to enhance vesicle release but not excessive enough to induce pathological changes. By optimizing stirring speed within 60-160 rpm, the system achieves adequate vesicle production while maintaining phenotype stability.
3Stability of the object's composition
If beta cells are cultured in tissue plates at laboratory scale, then phenotype is maintained, but scalability is limited
Solution Approach 1:
The patent transitions from two-dimensional adherent culture in tissue plates to three-dimensional suspension culture in bioreactors. This dimensional change enables scalability while maintaining phenotype through controlled stirring conditions, resolving the contradiction between phenotype preservation and productivity.
Solution Approach 2:
The suspension culture system with controlled stirring serves multiple functions: it maintains phenotype stability, enables scalable production, and ensures consistent extracellular vesicle release. This multi-functional approach resolves the contradiction between phenotype preservation and scalability for therapeutic applications.
4Quantity of substance
If large amounts of extracellular vesicles are produced for therapeutic use, then treatment efficacy is achieved, but production cost and complexity increase
Solution Approach 1:
The patent optimizes key parameters including stirring speed (60-160 rpm), culture duration (4-24 hours), and cell density to maximize extracellular vesicle yield per cell. These parameter optimizations reduce the overall scale of culture needed, thereby decreasing device complexity and production cost while achieving therapeutic quantities.
Solution Approach 2:
The suspension culture system with controlled stirring enables self-enhanced extracellular vesicle release without requiring complex intervention systems. The gentle agitation naturally promotes vesicle secretion and facilitates easy harvesting, reducing device complexity while producing sufficient quantities for therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method maintains high cell viability and produces extracellular vesicles with an unstressed phenotype, achieving higher yields suitable for therapeutic applications, addressing scalability and phenotype preservation challenges.
Implementation Method 1
culturing beta cells in the form of beta cell aggregates in suspension in a cell culture medium under stirring conditions
Data Source
AI summary
A method for obtaining extracellular vesicles from beta cells including at least a step (i) of culturing beta cells in the form of beta cell aggregates in suspension in a cell culture medium under stirring conditions to obtain extracellular vesicles from the beta cells. Also, the extracellular vesicles, in particular the small extracellular vesicles, obtainable by the method of the invention.